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Estimates suggest that those with serious mental illness are now
dying approximately 25 years earlier than the general population
and that up to 60% of premature deaths in those with serious
mental illness are as a result of general medical conditions.1 Studies
have shown that not only do patients with mood disorders
have more comorbid medical illnesses than mentally healthy
individuals,2–4 but also a greater medical illness burden (a greater
number of medical illnesses) seems to be associated with a more
severe clinical presentation of the mood illness.5 Traditionally,
the high prevalence of medical illness in those with mental health
problems has been viewed as a consequence of psychotropic
medications and an unhealthy lifestyle.6 However, recent research
has suggested that exposure to psychotropic medication does not
worsen mortality risk in patients with psychiatric illness7 and that
there may be underlying biological mechanisms linking mood
disorder and many medical illnesses.8,9
We have previously described the rates of physical disorders in
large samples of patients with recurrent depression (n= 1547) and
psychiatrically healthy controls (n= 884).10 The current study will
examine the rates of physical disorders in a large, well-defined,
sample of patients with bipolar affective disorder. These patients
were recruited and assessed using the same standardised
procedures as our recurrent depression and control participants
mentioned above. This will allow us to directly compare the rates
of each physical illness in our newly recruited bipolar sample with
our previously described recurrent depression and control samples.
In addition, the current study will investigate whether the presence
of medical illness in individuals with bipolar disorder is associated
with a more severe bipolar illness course. This is the first study
in a UK clinical population to assess rates of physical illnesses in
patients with a diagnosis of bipolar disorder and make direct
comparisons with unipolar and control samples.
Method
Participants
Participants were recruited at three UK sites (Birmingham, Cardiff
and London) as part of ongoing molecular genetic and clinical
studies of affective disorders.11,12 Individuals meeting DSM-IV13
and ICD-1014 criteria for bipolar disorder (n= 1720) were
included in the study. All participants were aged 18 years or older
and, because they were recruited for molecular genetic studies,
they were required to be of White European ethnicity. Individuals
were excluded if they: (a) had a lifetime diagnosis of intravenous
drug dependency; (b) had only experienced affective illness as
a result of alcohol or substance dependence; (c) had only
experienced affective illness secondary to medical illness or
medication; or (d) were biologically related to another study
participant. After complete description of the study to participants,
written informed consent was obtained.
Study assessment
Participants were interviewed using the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN).15 Psychiatric and family
practice case-notes were reviewed for the majority of participants.
Based on the SCAN interview information, and where available
the case-note information, lifetime diagnoses were made according
to DSM-IV and ICD-10 and ratings were made for key clinical
variables (for example, age at onset, presence of psychosis). Where
there was doubt regarding the diagnostic and clinical ratings the
case was rated independently by two research psychologists/
psychiatrists and consensus was reached. Regular interrater reliability
meetings were held within and across the three sites to ensure
consistency in diagnostic and ratings procedures.
Interrater reliability was formally assessed using joint ratings
for a subset of 20 participants with a range of mood disorder
diagnoses. Mean overall kappa statistics of 0.85 and 0.83 were
obtained for DSM-IV and ICD-0 diagnoses, respectively. Mean
kappa statistics and intraclass correlation coefficients (ICCs) for
other key clinical variables ranged from 0.81 to 0.99 and 0.85 to
0.97, respectively.
In order to establish the lifetime presence of physical health
disorders, a short self-report questionnaire was completed by
participants asking whether they had ever been told by a health
professional that they have any of the following 20 health problems:
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Background
Individuals with a mental health disorder appear to be at
increased risk of medical illness.
Aims
To examine rates of medical illnesses in patients with
bipolar disorder (n=1720) and to examine the clinical
course of the bipolar illness according to lifetime medical
illness burden.
Method
Participants recruited within the UK were asked about the
lifetime occurrence of 20 medical illnesses, interviewed using
the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN) and diagnosed according to DSM-IV criteria.
Results
We found significantly increased rates of several medical
illnesses in our bipolar sample. A high medical illness burden
was associated with a history of anxiety disorder, rapid
cycling mood episodes, suicide attempts and mood episodes
with a typically acute onset.
Conclusions
Bipolar disorder is associated with high rates of medical illness.
This comorbidity needs to be taken into account by services in
order to improve outcomes for patients with bipolar disorder
and also in research investigating the aetiology of affective
disorder where shared biological pathways may play a role.
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asthma, cancer, diabetes type 1, diabetes type 2, elevated lipids/
high cholesterol, epilepsy, gastric ulcers, heart disease, hyper-
tension, kidney disease, liver disease, memory loss/dementia,
migraine headaches, multiple sclerosis, osteoarthritis, osteoporosis,
Parkinson’s disease, rheumatoid arthritis, stroke, thyroid disease.
Responses were scored as ‘yes’, ‘no’ or ‘uncertain’. Where an
individual was coded ‘uncertain’ for a particular illness, they were
excluded from analyses for that medical illness. The study received
all necessary Multi-Region and Local Research Ethics Committee
(MREC and LREC) approval.
The unipolar and control samples used as comparison groups
have previously been described in Farmer et al.10 In brief,
participants meeting DSM-IV and ICD-10 criteria for recurrent
major depression (unipolar depression: n=1737) were recruited
and assessed (as part of the Depression Case Control DeCC study)
using the procedures and assessments described above for the
bipolar sample. In addition, individuals in the unipolar group
were excluded if they (a) had a first- or second-degree relative with
a diagnosis of bipolar affective disorder, schizophrenia, schizotypal
disorder, delusional disorder, acute and transient psychotic disorders
or schizoaffective disorder, or (b) had ever experienced mood
incongruent psychosis or psychosis outside of mood episodes.
The control group (n= 1340) were recruited to the London
site via the Medical Research Council (MRC) general practice
research framework (n=846) or were staff or student volunteers
of King’s College London (n=494). Individuals were included if
they were 18 years or older and were of White European origin.
Control participants recruited via the MRC general practice
research framework were screened using the Sham et al16
composite index (G) of depressive and anxiety symptoms and
then telephone interviewed using the Past History Schedule
(PHS)17 to screen for lifetime absence of psychiatric disorder.
The volunteers from King’s College London were interviewed in
person and screened using the PHS (n=494).
The control group also completed the short self-report
medical illness questionnaire described above.
Data analysis
Rates of medical illnesses across the bipolar,
unipolar and control groups.
Sociodemographic characteristics were compared between the
bipolar, unipolar and control groups using chi-squared tests for
categorical variables and Kruskal–Wallis tests for non-parametric
continuous variables. Group comparisons of the lifetime prevalence
of each of the different medical conditions were performed using
chi-squared tests and pair-wise binary logistic regression analyses
for each medical condition, with diagnostic group as the outcome
variable. As there were significant gender differences between the
three groups, gender was also entered into the logistic regression
models as a cofactor. Since medical disorders occur more frequently
with increasing age and there were significant differences in age at
interview between the groups, age at interview was also included
as a cofactor.
We used the Bonferroni method to conservatively correct for
multiple testing. As there were three groups with 20 medical
illnesses (3620=60), P-values from the logistic regression analyses
were multiplied by 60.
Rates of medical illness according to bipolar subtype
We then compared the lifetime prevalence of each of the different
medical conditions in the bipolar I disorder (bipolar I) group and
the bipolar II disorder (bipolar II) group using chi-squared tests
and logistic regression. Again, gender and age were included as
cofactors in the logistic regression models and the Bonferroni
method was used to correct for multiple testing. As we were
comparing 20 medical illnesses, P-values from the logistic
regression analyses were multiplied by 20.
Clinical characteristics of bipolar disorder
according to medical illness burden
For a subsample of the bipolar group (n=1216), detailed clinical
information regarding the course and clinical features of the
bipolar illness was available. As previous studies have shown that
a higher burden of medical illness is associated with a more severe
illness course in bipolar disorder, we compared sociodemographic
and clinical features in those bipolar participants with a high
medical illness burden (history of three or more medical illnesses
(bipolar+3M)) to those with no history of medical illness
(bipolar+0M) using chi-squared tests for categorical variables
and Mann–Whitney U-tests for non-parametric continuous
variables. A cut-off of three or more medical illnesses was selected
as previous studies have shown that patients with multiple
conditions (defined as three or more medical conditions) are
significantly more likely to have a mental illness18 and that, when
focusing on the number of either medical or psychiatric illnesses,
the lifetime presence of three or more conditions is associated
with increased disability, lower life expectancy and increased
health spending.19
A binary logistic regression analysis was carried out with
group status (bipolar+3M/bipolar+0M) as the outcome variable.
Gender, age at interview and the clinical features that were
significantly different between the two groups (P50.05) in the
univariate analyses were entered as cofactors to establish which
clinical features best predicted medical illness burden group status.
All analyses were undertaken using the Statistical Procedures for
the Social Sciences (SPSS) version 20 for Windows.
Results
The control group (n=1340) was significantly younger at
interview compared with the bipolar (n= 1720) and unipolar
(n=1737) groups (bipolar, unipolar4control: P50.0001). The
median age at interview (and range) in years for the bipolar,
unipolar, and control groups was 47 (18–84), 47 (18–85) and 44
(18–91), respectively. The proportion of women was higher in
the bipolar and unipolar groups compared with the control group
(bipolar, unipolar4control: P50.0001), with women comprising
70%, 71% and 57% of the bipolar, unipolar and control groups
respectively.
Rates of medical illnesses across the bipolar,
unipolar and control groups
The lifetime rates of self-reported medical illnesses in the bipolar,
unipolar and control groups are shown in Table 1. Significant
differences between groups were found in the lifetime prevalence
of all medical illnesses with the exception of type 1 diabetes.
To examine differences in the rate of each medical illness
between the three groups, accounting for gender and age at
interview, binary logistic regression was carried out for all medical
illnesses showing a significant (P50.05) between-group difference
in the univariate analyses. Diagnostic group was entered as the
outcome variable and presence/absence of the medical disorder,
gender and age at interview were entered as cofactors. Odds ratios,
95% confidence intervals and P-values for each logistic regression
analysis are shown in Table 2. Following correction for multiple
testing, using the Bonferroni method, statistically significant
differences in the rates of ten medical illnesses remained between
the three groups (Fig. 1).
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Rates of medical illness according
to bipolar subtype
Table 3 shows the lifetime rates of self-reported medical illness
according to bipolar subtype and the results of the binary logistic
regression analyses with diagnostic group (bipolar I v. bipolar II) as
the outcome variable and presence/absence of each medical disorder,
gender and age at interview as cofactors. The rates of gastric ulcers,
heart disease, Parkinson’s disease and rheumatoid arthritis were
significantly higher in the bipolar II group. There was a significantly
higher rate of kidney disease in the bipolar I group. These differences
were not statistically significant following correction for multiple
testing using the Bonferroni method.
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Table 1 Lifetime rates (%) of self-reported medical illnesses in bipolar, unipolar and control groups
Medical illness
Bipolar group, %
(n=1720)
Unipolar group, %
(n=1737)
Control group, %
(n=1340)
Asthma 19.2 13.1 10.7
Cancera 3.6 4.5 2.7
Diabetes type 1 1.2 1.2 0.8
Diabetes type 2 4.8 2.7 1.0
Elevated lipids 19.2 9.7 5.3
Epilepsy 3.4 2.0 0.5
Gastric ulcersa 4.5 4.8 1.2
Heart disease 2.6 3.5 1.1
Hypertension 15.0 16.8 6.2
Kidney diseasea 3.0 1.7 1.1
Liver diseasea 1.2 2.0 0.9
Memory loss/dementia 2.0 1.8 0.0
Migraine headaches 23.7 21.9 16.5
Multiple sclerosis 0.5 7.1 0.0
Osteoarthritis 10.8 10.9 3.0
Osteoporosis 2.6 3.0 1.0
Parkinson’s disease 0.6 0.1 0.1
Rheumatoid arthritis 4.4 4.3 2.0
Stroke 2.5 1.6 0.3
Thyroid diseasea 12.9 8.2 2.5
a. Data only available for a subset of the bipolar disorder group (n=1216).
Table 2 Binary logistic regression with diagnostic group (bipolar/unipolar, bipolar/control, unipolar/control) as the outcome
variable and presence/absence of the medical disorder, gender and age at interview as cofactors (prior to Bonferroni correction)a
Bipolar/unipolar group Bipolar/control group Unipolar/control group
Medical illness OR (95% CI) P OR (95% CI) P OR (95% CI) P
Asthma 1.60 (1.33–1.93) 5.6761077 2.17 (1.74–2.71) 5.45610712 1.37 (1.09–1.73) 0.008
Cancerb 0.79 (0.53–1.16) 0.224 1.36 (0.78–2.36) 0.274 1.79 (1.08–2.97) 0.024
Diabetes type 1 0.98 (0.53–1.81) 0.936 1.56 (0.73–3.36) 0.252 1.42 (0.67–3.03) 0.360
Diabetes type 2 1.87 (1.30–2.70) 0.001 4.14 (2.28–7.53) 3.0961076 2.34 (1.19–4.20) 0.012
Elevated lipids 2.33 (1.90–2.86) 6.46610716 3.52 (2.66–4.64) 6.11610719 1.48 (1.09–1.99) 0.011
Epilepsy 1.73 (1.13–2.65) 0.012 6.19 (2.79–13.73) 7.2861076 3.88 (1.71–8.83) 0.001
Gastric ulcersb 0.95 (0.66–1.35) 0.76 4.53 (2.21–9.30) 3.8761075 4.69 (2.34–9.44) 1.3761075
Heart disease 0.71 (0.47–1.06) 0.095 1.75 (0.95–3.21) 0.073 2.61 (1.46–4.68) 0.001
Hypertension 0.89 (0.73–1.07) 0.210 2.16 (1.65–2.83) 2.2561078 2.44 (1.87–3.18) 5.70610711
Kidney diseaseb 1.86 (1.13–3.07) 0.015 4.66 (2.03–10.66) 2.7661074 1.95 (0.84–4.50) 0.118
Liver diseaseb 0.47 (0.24–0.93) 0.029 1.01 (0.40–2.55) 0.985 2.36 (1.08–5.16) 0.031
Memory loss/dementia 1.13 (0.69–1.85) 0.625 24.3 (3.29–178.8) 0.002 20.1 (2.71–148.5) 0.003
Migraine headaches 1.13 (0.96–1.33) 0.147 1.39 (1.15–1.69) 0.001 1.20 (0.99–1.46) 0.064
Multiple sclerosis 0.06 (0.03–0.129) 4.34610714 7.01 (0.86–57.21) 0.069 88.3 (12.3–633.7) 8.3761076
Osteoarthritis 0.99 (0.79–1.25) 0.950 2.65 (1.84–3.82) 1.7461077 2.69 (1.87–3.86) 1.0461077
Osteoporosis 0.89 (0.59–1.34) 0.564 1.75 (0.91–3.30) 0.086 1.86 (0.99–3.49) 0.052
Parkinson’s disease 5.7 (1.26–25.79) 0.024 5.97 (0.76–46.90) 0.09 1.61 (0.15–17.86) 0.697
Rheumatoid arthritis 1.04 (0.74–1.44) 0.839 1.92 (1.19–3.10) 0.007 2.06 (1.28–3.22) 0.003
Stroke 1.49 (0.91–4.43) 0.113 5.60 (1.98–15.83) 0.001 4.08 (1.41–11.76) 0.009
Thyroid diseaseb 1.70 (1.32–2.18) 3.3161075 6.26 (3.77–10.40) 1.43610712 3.46 (2.09–5.73) 1.3361076
a. Results in bold are statistically significant at P50.05.
b. Data only available for a subset of the bipolar disorder group (n=1216).
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Clinical characteristics of bipolar disorder according
to medical illness burden
In order to investigate whether a greater burden of medical illness
is associated with a more severe bipolar illness course, we
compared those participants who had a history of three or more
medical illnesses (bipolar+3M: n= 202) with those with no
medical illnesses (bipolar+0M: n= 440) (Table 4, see online Table
DS1 for a more detailed version of this table). A number of
variables appeared to be associated with an increase in medical
illness burden. These included: a longer illness duration, a
typically acute onset of mood episodes, a greater number of
psychiatric in-patient admissions, deterioration in functioning,
increased rates of anxiety disorder, suicide attempt, rapid cycling,
and treatment with anxiolytics, mood stabilisers and electro-
convulsive therapy (ECT). When controlling for age at interview,
the association with each of the following three variables was no
longer statistically significant: number of admissions, lifetime
treatment with mood stabiliser or ECT.
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Fig. 1 Rates of medical illnesses showing statistically significant differences between groups following Bonferroni correction for multiple
testing.
Statistically significant between group differences (P50.001) following Bonferroni correction: bipolar4unipolar disorder, control group: asthma, elevated lipids; bipolar disorder
4control group: diabetes type 2, epilepsy, kidney disease; unipolar, bipolar disorder4control group: gastric ulcers, hypertension, osteoarthritis; unipolar4bipolar disorder, control
group: multiple sclerosis; bipolar4unipolar4control group: thyroid disease.
Table 3 Lifetime rates (%) of self-reported medical illness according to bipolar subtype and binary logistic regression with
diagnostic group (bipolar I v. bipolar II) as the outcome variable and presence/absence of the medical disorder, gender and age at
interview as cofactors (prior to Bonferroni correction)
Medical illness
Bipolar I, %
(n = 856, 70.4%)
Bipolar II, %
(n=360, 29.6%) OR (95% CI) P
Asthma 19.5 19.2 0.98 (0.72–1.35) 0.909
Cancer 3.7 3.3 1.10 (0.55–2.19) 0.795
Diabetes type 1 0.6 1.1 1.83 (0.49–6.89) 0.373
Diabetes type 2 4.3 3.9 0.97 (0.52–1.86) 0.966
Elevated lipids 20.9 19.7 1.01 (0.73–1.40) 0.944
Epilepsy 2.1 2.2 1.08 (0.47–2.50) 0.853
Gastric ulcers 3.6 6.4 1.98 (1.13–3.47) 0.017
Heart disease 1.6 3.1 2.45 (1.07–5.60) 0.034
Hypertension 13.1 15.1 1.30 (0.91–1.88) 0.152
Kidney disease 3.9 0.8 0.24 (0.07–0.80) 0.020
Liver disease 1.1 1.4 1.69 (0.49–5.89) 0.41
Memory loss/dementia 1.4 2 1.32 (0.49–1.32) 0.587
Migraine headaches 20.6 23 1.17 (0.86–1.59) 0.313
Multiple sclerosis 0.2 0 0.00 (0.00) 0.999
Osteoarthritis 9.8 10.4 1.32 (0.85–2.05) 0.214
Osteoporosis 1.9 1.4 0.94 (0.34–2.60) 0.904
Parkinson’s disease 0.1 0.8 10.45 (1.06–102.6) 0.044
Rheumatoid arthritis 2.6 4.5 2.05 (1.05–4.00) 0.035
Stroke 1.8 2 1.18 (0.45–3.12) 0.739
Thyroid disease 13.3 11.9 0.99 (0.66–1.49) 0.982
a. Results in bold are statistically significant at P50.05.
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To identify the clinical characteristics of bipolar illness that
best predict medical illness burden group, we entered the variables
that were statistically significant at the P50.05 level in the
univariate analyses, shown in Table 4, into a logistic regression
model. Age at interview and gender were also entered into the
model. The clinical characteristics that best predicted high medical
illness burden group were having a lifetime history of anxiety
disorder (OR= 2.76, 95% CI 1.49–5.13, P= 0.001), rapid cycling
mood episodes (OR= 2.25, 95% CI 1.20–4.25, P=0.012), suicide
attempt (OR= 2.39, 95% CI 1.30–4.39, P=0.005) and mood
episodes with a typically acute onset (within a week)
(OR= 2.56, 95% CI 1.17–5.62, P= 0.019).
Discussion
Rates of medical illnesses across the bipolar,
unipolar and control groups
The most prevalent medical conditions in the bipolar sample were
migraine headache (23.7%), asthma (19.2%), elevated lipids
(19.2%), hypertension (15%), thyroid disease (12.9%) and
osteoarthritis (10.8%). The same six conditions were also the most
prevalent conditions in the unipolar sample: migraine headache
(21.9%), asthma (13.1%), elevated lipids (9.7%), hypertension
(16.8%), thyroid disease (8.2%) and osteoarthritis (10.9%).
The high rates of migraine headache in these samples are
consistent with previous findings.3,20 The high comorbidity
between affective disorder and migraine may be because of a
causal relationship, with one disorder causing (or increasing risk
for) the other, or may be because of shared aetiological factors.
As studies show that the combination of these two disorders cause
more impairment than either disorder alone21 it is important to
make sure that the patients are screened and treated appropriately
to ensure the optimal outcome for the patient.
Almost a fifth of our bipolar sample (19.2%) self-reported a
lifetime history of asthma. This figure is comparable to the rate
of 15.9% reported by McIntyre et al20 in their bipolar sample. A
recent study has suggested that childhood asthma increases the
risk of bipolar disorder developing in adulthood.22 Again this
leads to a number of hypotheses regarding the relationship
between affective disorders and asthma in terms of aetiology
and causation, with the possibility, for example, that carbon
dioxide hypersensitivity and corticosteroid therapy may partly
explain this association.
The increased rates of hypertension in our affective disorders
samples are again consistent with previous research, although
rates across studies vary according to the age ranges of
participants.3,23,24 D’Mello25 found that hypertension seemed
to be related to the severity of illness in bipolar disorder with
increased levels of hypertension found in those patients with
higher levels of mania.
The literature concerning the relationship between mood
disorders and cholesterol levels is inconsistent, with studies
suggesting that lower levels are associated with current suicide risk
469
Table 4 Clinical features and course of bipolar illness in participants with bipolar disorder with a high burden of comorbid
medical illness (three or more medical illnesses, bipolar+3M) compared with those participants with bipolar disorder with no history
of medical illness (bipolar+0M) (see online Table DS1 for a more detailed version of this table)
Bipolar+0M (n=440)a Bipolar+3M (n=202)a P
DSM-IV, n (%)
Bipolar I disorder 314 (71.4) 140 (69.3) 0.641
Bipolar II disorder 126 (28.6) 62 (30.7)
Illness duration, years: median (IQR) range 19 (1–57) 16 32 (4–57) 14.75 50.0001
Age at onset, years: median (IQR) range 20 (7–55) 10 20 (6–61) 12 0.925
Onset of mood episodes typically acute, within a week, n (%)
Yes 41 (9.3) 32 (15.8) 0.012
No 399 (90.7) 170 (84.2)
Total number of psychiatric admissions lifetime ever
Median (mean) 2 (2) 2 (4.3) 50.0001
IQR (range) 0–25 (3) 0–61 (5)
Anxiety disorder present lifetime ever, n (%)
Yes 193 (49.9) 145 (75.1) 50.0001
No 194 (50.1) 48 (24.9)
Suicide attempt present lifetime ever, n (%)
Yes 215 (48.9) 124 (61.4) 0.002
No 225 (51.1) 78 (38.6)
Rapid cycling present lifetime ever, n (%)
Yes 99 (33.2) 59 (45.4) 0.011
No 199 (66.8) 71 (54.6)
Deterioration in functioning, n (%)
Yes 143 (39.7) 81 (52.9) 0.004
No 217 (60.3) 72 (47.1)
Ever taken anxiolytics, n (%)
Yes 258 (61.9) 138 (75.8) 0.001
No 159 (38.1) 44 (24.2)
Ever taken mood stabilisers, n (%)
Yes 358 (83.4) 170 (89.5) 0.031
No 71 (16.6) 20 (10.5)
Electroconvulsive therapy, n (%)
Yes 64 (14.8) 57 (29.8) 0.000016
No 368 (85.2) 134 (70.2)
a. For some variables because of missing data n is less than n=440 and n=202 for BD+0M and BD+3M, respectively.
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and depressive and manic symptoms26 but that people with
bipolar disorder are at higher risk of metabolic abnormalities
including obesity and hyperlipidemia,27 consistent with the
increased rates of hyperlipidaemia found in our bipolar sample.
Our finding of increased rates of thyroid disorder in those with
mood disorders is not surprising, given the well-established link
between thyroid dysfunction and mood disorders.28,29 Thyroid
problems are a common side-effect of the drug lithium, which
is a common treatment for bipolar disorder and is also used to
treat severe or treatment-resistant unipolar depression. In our
bipolar sample, rates of thyroid disorder were significantly
increased in those who had taken mood stabilising medication
during their lifetime.
A recent study highlighted that the amount of pain people
with osteoarthritis feel appears to be directly related to their
mental health,30 however, our study, which found significantly
higher rates of osteoarthritis in patients with mood disorders
compared with controls, is the first to examine the rates of
osteoarthritis in people with unipolar and bipolar disorders.
Studies have shown increased rates of depression in patients with
arthritis (of any type) with the temporal relationship indicating
that arthritis predicts new onset of psychiatric disorder.31 The
results of previous studies have been conflicting in terms of
investigating the relationship between osteoporosis and mood
disorder.32 This is the largest study to date to examine rates of
osteoporosis in bipolar disorder and we found no distinction
between the bipolar, unipolar and control samples in terms of
the rate of osteoporosis.
We found higher rates of kidney disease in the bipolar sample
compared with controls, with rates being highest in patients with
bipolar I compared with bipolar II disorder. Again, this finding is
consistent with previous research29 and is not surprising, given the
adverse renal effects that have been associated with lithium
therapy,33 which vary from the more common reversible polyuria
to irreversible kidney damage. Similarly, the increased rate of
Parkinson’s disease reported in our bipolar sample compared with
the unipolar sample and controls may be related to the greater use
of antipsychotic medications and selective serotonin reuptake
inhibitors in the bipolar sample, in that patients may be reporting
symptoms occurring as a side-effect of their medication, rather
than Parkinson’s disease.
Our finding of increased rates of epilepsy in the bipolar group
compared with controls is consistent with previous research29
including a study indicating that the rate of bipolar spectrum
disorders in individuals with epilepsy is higher than that seen in
the general population.34 In our study, multiple sclerosis was
significantly more common in those with unipolar disorder
compared with those with bipolar disorder and controls, with
the rates being 7%, 0.5%, 0%, respectively; a finding not
previously described. However, this finding is consistent with
previous reports that have found the prevalence of major
depression to be elevated in people with multiple sclerosis
compared with those without multiple sclerosis and those
reporting other chronic conditions.35,36 Recent studies have
suggested that biological processes may account for the overlap
between depression and multiple sclerosis, rather than depression
simply being a psychological reaction to the burden of being ill.37
Rates of medical illness according to bipolar subtype
To our knowledge, this is the first study to look at rates of medical
comorbidities across large samples of patients with bipolar I and II
disorders. In patients with bipolar disorder, the type of bipolar
disorder (I or II) may be associated with an increased risk of
certain medical illnesses. Participants with bipolar II disorder
may be more likely to have gastric ulcers, heart disease,
Parkinson’s disease and rheumatoid arthritis than patients with
a diagnosis of bipolar I disorder. Participants with bipolar I
disorder were significantly more likely to have had kidney disease
than those with bipolar II disorder. It is important to note,
however, that the statistically significant differences between the
bipolar I and II groups did not remain following correction for
multiple testing.
Clinical characteristics of bipolar disorder according
to medical illness burden
We have also demonstrated that in those with bipolar disorder, a
higher burden of medical illness is associated with certain clinical
features indicative of a more severe illness course, with greater
impairment in functioning. These results are in agreement with
previously reported findings38,39 that increased medical burden
is linked with more suicide attempts, older age and longer illness
duration.
Previous reports have attributed poor physical health in
people with mental ill to increased rates of smoking and alcohol
misuse (and other lifestyle factors).40,41 In our bipolar sample,
we found no statistically significant differences between the
bipolar group with no history of medical illness and those with
a high burden of medical illness in terms of rates of alcohol misuse
or smoking. Although this finding requires further investigation it
suggests that, at least in our bipolar sample, smoking and alcohol
misuse may not be the most significant factors influencing
susceptibility to medical illness burden. This finding is in line with
the findings of Chwastiak et al,42 who reported no association
between an increased number of medical conditions and alcohol
or drug misuse in patients with schizophrenia. We found higher
lifetime rates of treatment with anxiolytics, mood stabilisers and
ECT in those with a higher medical illness burden, although after
controlling for age at interview, this finding remained only for
lifetime treatment with anxiolytics, which is consistent with the
higher rates of anxiety disorders found in those with a higher
medical illness burden.
The mechanisms underlying the relationship between mental
and physical health disorders are complex, although evidence
suggests that the causal relationships are likely to be bidirectional.4,9
The existence of a medical condition may be a stress that increases
the risk of developing a mood episode/disorder. Similarly, the
existence of an affective disorder may increase the risk of developing
a medical condition.
Research findings to date suggest that affective disorders may
share some aetiological factors in common with certain medical
disorders. A pathway analysis of Wellcome Trust Case Control
Consortium genome-wide association study data suggested that
bipolar disorder and metabolic disorders, such as coronary artery
disease and diabetes type 2, have strong genetic links and may
share some common pathophysiological pathways.43 Such
findings suggest that subphenotypes defined by the presence of
certain comorbid medical conditions are likely to be useful in
studies investigating the genetic aetiology of mood disorders.
The findings of Rztetsky et al8 suggest that many complex
phenotypes (non-Mendelian disorders including both physical
and psychiatric disorders) are probably rooted in genetic variation
that is significantly shared by multiple disease phenotypes.
Strengths and limitations
The strengths of our study include the use of large, well-defined
samples of patients, recruited from throughout the UK and
assessed using standardised methodology. It is important to
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consider our findings in light of certain limitations. First, our rates
of medical illness rely on a self-report measure. The accuracy of
this self-report measure was assessed by Farmer et al,10 where 61
patient self-reports were compared with reports from the patient’s
general practitioner (GP) about the medical illnesses the patient
had been treated for. Kappa statistics for self-report compared
with GP report for six of the more common disorders were
calculated with results as follows: asthma k= 0.73, diabetes
k= 0.91, hypertension k= 0.87, hypercholesterolaemia k= 0.65,
heart attack/angina k=0.82 and arthritis k=0.74. Percentage
agreement between GPs and participants for the presence or
absence of a medical disorder was 93%. In addition, ten of the
medical illnesses included in the current study were also included
in a study by Carney & Jones3 which examined in-patient and
out-patient administrative claims in the USA. The rates of medical
disorders seen in their bipolar and control samples were reassuringly
similar to those seen in the current study.
A second limitation is that we do not have a consistent
measure of body mass index (BMI, or of waist/hip ratio) across
all of our samples. When comparing BMI between participants
with unipolar depression and controls, Farmer et al10 found that
although the two groups were similarly represented in the over-
weight range, the unipolar depression group were significantly
overrepresented in the obese range. In the Famer et al10 study,
obesity was associated with an increase in self-reported rates of
hypercholesterolaemia, type 2 diabetes and myocardial infarction.
These findings suggest that some of the results from the current
study may be altered if we were to control for BMI. Here, BMI
could be seen as a confounding factor or an intermediate
phenotype with potentially shared heritable pathogenesis. Third,
our sample was restricted to a single ethnic group, limiting the
generalisability of our findings. Fourth, it is possible that the
voluntary nature of the control sample may have resulted in an
unrepresentatively healthy sample with an artificially low
prevalence of medical illnesses. Finally, we did not have data on
some additional lifestyle factors such as diet or activity that may
be related to medical illness burden.
Implications
These findings suggest that patients with affective disorders have
an increased risk of certain medical conditions. Knowledge of
the most prevalent medical conditions in patients with affective
disorders and developments in the prevention, detection and
treatment of such illnesses in this group are essential in improving
care and prognosis. It is important to raise awareness among
healthcare professionals about the risks to which patients with
affective disorders are exposed. Knowing which medical illnesses
are likely to coexist with a mood disorder may help to improve
diagnostics and management and therefore clinical and social care
for patients. Early diagnostics and treatment of medical conditions
are necessary to prevent mortality and unfavourable outcomes in
terms of both physical and mental health.
Although the relationship between affective disorders and
physical conditions is not fully understood, it is likely that some
of the risk factors for comorbid psychiatric and medical illness
are modifiable. Further research on this subject may help to
improve quality of life, prognosis and life expectancy for those
with these illnesses. Compared with individuals with no history
of mental illness, individuals with bipolar disorder are at increased
risk of premature death, from both natural and unnatural
causes.44 A growing evidence base suggests that more integrated
ways of working, with collaboration between mental health and
other professionals, offers the best chance of improving outcomes
for individuals with both mental health and physical conditions.45
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